SLC and Biotechmave colloquy: BioTechMaven T

Quote:

---

BioTechMaven Thursday, 05/18/17 10:14:21 PM
Re: slcimmuno post# 182542
Post # of 182568

Solid post. Zero doubt Cellceutix is in the sweet spot for partnership or acquisition. 2Q17.

---

Quote:

---

slcimmuno Member Level Thursday, 05/18/17 11:00:23 PM
Re: BioTechMaven post# 182550
Post # of 182568

Yep - CTIX doing their Ph2 PoC trials the right way... link below relevant to Kevetrin and Ovarian Cancer.

Prove your drug is more reality than mere concept, having done the early heavy lifting of sifting potential winners from definite losers (ID lead Compounds), test in humans and show compelling results, and Big Rx likely will step up and pay up.

Tick-tock. Tick-tock. Tick-tock.

B / P / K : Three strong shots on goal, Eden Hazard-like.

//

"Factors associated with failure of oncology drugs in late-stage clinical development: A systematic review"
(Jan 17)

Drug development in oncology is characterized by a high rate of failure at the stage of phase III trials.
•
Achieving proof of concept based on drug activity after a phase II trial increases the likelihood of later approval.
•
Drugs developed under a biomarker-based selection strategy are less likely to fail at late stages of development.

http://www.sciencedirect.com/science/article/...7216301165

---